GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...

In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...

Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...

On March 6, 2025, the Federal Trade Commission (FTC) filed a lawsuit in federal court challenging GTCR BC Holdings, LLC's (GTCR) proposed ...

The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate significant head-to-head competition.” ...

The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...

Lake Street Capital upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a hold rating to a buy rating in a report published on Friday morning, Marketbeat.com reports. Lake Street Capital ...

The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.

The Federal Trade Commission on March 6 sued to block GTCR’ s acquisition of Surmodics, alleging that “the deal, which seeks to combine the two largest manufacturers of critical medical device ...